SCHEMBL3835829

SCHEMBL3835829

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(CN(CCCN2CCOCC2)C(=O)Nc2ccc3c(c2)OCCO3)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
LMNA P02545 5/20 0.50
TP53 P04637 2/20 0.50
POLB P06746 1/20 0.50
RAB9A P51151 1/20 0.50
KDM4E B2RXH2 5/20 0.48
HPGD P15428 5/20 0.48
HSD17B10 Q99714 5/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GLA P06280 1/20 0.48
TSHR P16473 4/20 0.48
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
ATM Q13315 1/20 0.46
USP2 O75604 2/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
CD274 Q9NZQ7 1/20 0.45
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3836123 0.96 LMNA (0.51) ALDH1A1LMNATP53POLBRAB9A
SCHEMBL3830687 0.96 ALDH1A1 (0.51) ALDH1A1LMNATP53POLBRAB9A
SCHEMBL3835546 0.95 PIR (0.44) ALDH1A1LMNATP53POLBRAB9A
SCHEMBL2475671 0.94 TSHR (0.43) ALDH1A1LMNATP53POLBRAB9A
SCHEMBL7998011 0.93 ALDH1A1 (0.49) ALDH1A1LMNATP53POLBRAB9A
SCHEMBL3832780 0.92 TSHR (0.48) ALDH1A1LMNATP53KDM4EHPGD
SCHEMBL3835037 0.92 KDM4E (0.45) ALDH1A1LMNATP53POLBRAB9A
SCHEMBL3834058 0.92 KDM1A (0.41) ALDH1A1LMNATP53POLBRAB9A
SCHEMBL3221268 0.90 USP2 (0.49) ALDH1A1LMNATP53POLBRAB9A
SCHEMBL3835723 0.90 RAB9A (0.44) ALDH1A1LMNATP53POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 ALDH1A1 1040/4885LMNA 877/4885TP53 3798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.